Analytical strategies for identifying drug metabolites

Mass Spectrometry Reviews

Volumn 26, Issue 3, 2007, Pages 340-369

  Prakash, Chandra ^a   Shaffer, Christopher L ^a   Nedderman, Angus ^b  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Biotransformation; Derivatization; H D exchange; LC MS MS; LC NMR; Metabolites; Structural characterization

Indexed keywords

BIOLOGICAL MATRICES; BIOTRANSFORMATION; HYDROGEN/DEUTERIUM EXCHANGE (H/D EXCHANGE); STRUCTURAL CHARACTERIZATION;

BIOASSAY; ENZYME ACTIVITY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLITES; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

PHARMACOKINETICS;

DRUG;

ARTICLE; CHEMISTRY; CHROMATOGRAPHY; DEUTERIUM HYDROGEN EXCHANGE; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

CHEMISTRY, ANALYTICAL; CHROMATOGRAPHY; DEUTERIUM EXCHANGE MEASUREMENT; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; PHARMACEUTICAL PREPARATIONS;

EID: 34248582576     PISSN: 02777037     EISSN: None     Source Type: Journal    
DOI: 10.1002/mas.20128     Document Type: Article

References (179)

1. Alavijeh MS, Palmer AM. 2004. The pivotal role of drug metabolism and pharmacokinetics in the discovery and development of new medicines. Invest Drugs 7:755-763.
2. Anari MR, Baillie TA. 2005. Bridging cheminformatic metabolite predictions and tandem mass spectrometry. Drug Discov Today 10:711-717.
3. Anari MR, Bakhtiar R, Zhu B, Huskey S, Franklin RB, Evan D. 2002. Derivatization of ethinylestradiol with dansyl chloride to enhance electrospray ionization: Application in trace analysis of ethinylestradiol in rhesus monkey plasma. Anal Chem 74:4136-4144.
4. Axelsson B-O, Jornten-Karlsson M, Michelsen P, Abou-Shakra F. 2001. The potential of inductively coupled plasma mass spectrometry detection for high-performance liquid chromatography combined with accurate mass measurement of organic pharmaceutical compounds. Rapid Commun Mass Spectrom 15:375-385.
5. Ayrton J, Dear GJ, Leavens WJ, Mallet DN, Plumb RS. 1997. The use of turbulent flow chromatography/mass spectrometry for the rapid, direct analysis of a novel pharmaceutical compound in plasma. Rapid Commun Mass Spectrom 11:1953-1958.
6. Baillie TA. 2003. Chemically reactive metabolites in drug discovery and development. In: Lee JS, Fisher M, Obach RS, editors. Drug metabolizing enzymes: Cytochrome p450 and other enzymes in drug discovery and development. New York: Marcel Dekker. pp 147-154.
7. Baillie TA, Cayen MN, Fouda HG, Gerson RJ, Gree JD, Grossman SJ, Klunk LJ, LeBlanc B, Perkins DG, Shipley LA. 2002. Drug metabolites in safety testing. Toxicol Appl Pharmacol 182:188-196.
8. Barker J, Gamer RC. 1999. Biomedical applications of accelerator mass spectrometry-isotope measurements at the level of the atom. Rapid Commun Mass Spectrom 13:285-293.
9. Barry SJ, Carr RM, Lane SJ, Leavens WJ, Monte S, Waterhouse I. 2003. Derivatization for liquid chromatography/electrospray mass spectrometry: Synthesis of pyridinium compounds and their amine and carboxylic acid derivatives. Rapid Commun Mass Spectrom 17:603-620.
10. Bennett CL, Beukens RP, Clover MR, Gove HE, Liebert RB, Litherland AE, Purser KH, Sondheim WE. 1977. Radiocarbon dating using electrostatic accelerators: Negative ions provide the key. Science 198:508-510.
11. Bergstrom SK, Markides KE. 2002. On-line coupling of microdialysis to packed capillary column liquid-chromatography-tandem mass spectrometry demonstrated by measurement of free concentrations of ropivacaine and metabolite from spiked plasma samples. J Chromatogr B 775:79-87.
12. Blair I, Tilve A. 2002. Analysis of anticancer drugs and their metabolites by mass spectrometry. Curr Drug Metab 3:463-480.
13. Boernsen KO, Floeckher JM, Bruin GJM. 2000. Use of a microplate scintillation counter as a radioactivity detector for miniaturized separation techniques in drug metabolism. Anal Chem 72:3956-3959.
14. Brown SC, Kruppa G, Dasseux J-L. 2005. Metabolomics applications of FT-ICR mass spectrometry. Mass Spectrom Rev 24:223-231.
15. Bruins AP. 1991. Mass spectrometry with ion sources operating at atmospheric pressure. Mass Spectrom Rev 10:53-77.
16. Caldwell J. 1996. The Role of drug metabolism studies for efficient drug discovery and development: Opportunities to enhance time- and cost-efficiency. J Pharm Sci 2:117-119.
17. Castro-Perez J, Plumb R, Granger JH, Beattie I, Joncour K, Wright A. 2005. Increasing throughput and information content for in vitro drug metabolism experiments using ultra-performance liquid chromatography coupled to a quadrupole time-of-flight mass spectrometer. Rapid Commun Mass Spectrom 19:843-848.
18. Charlesworth JM. 1978. Evaporative analyzer as a mass detector for liquid chromatography. Anal Chem 50:1414-1420.
19. Chen WG, Zhang C, Avery MJ, Fouda HG. 2001. Reactive metabolite screen for reducing candidate attrition in drug discovery. Adv Exp Med Biol 500:521-524.
20. Chen XY, Zhao LM, Zhong DF. 2003. A novel metabolic pathway of morphine: Formation of morphine glucosides in cancer patients. Br J Clin Pharmacol 55:570-578.
21. Christie WW. 1998. Gas chromatography-mass spectrometry methods for structural analysis of fatty acids. Lipids 33:343-353.
22. Clarke NJ, Rindgen D, Korfmacher WA, Cox KA. 2001. Systematic LC/MS metabolite identification in drug discovery. Anal Chem A-Pages 73:430A-439A.
23. Clayton J. 2005. Go with the microflow. Nat Methods 2:612-616.
24. Corcoran O, Spraul M. 2003. LC-NMR-MS in drug discovery. Drug Discov Today 8:624-631.
25. Covey TR, Lee ED, Bruins AP, Henion JD. 1986. Liquid chromatography/mass spectrometry. Anal Chem 58:1451A-1461A.
26. Cox KA. 2005. Special requirements for metabolite characterization. In: Korfmacher WA, editor. Using mass spectrometry for drug metabolism studies. Boca Raton, FL: CRC Press, pp 229-252.
27. Coym JW, Dorsey JG. 2004. Superheated water chromatography: A brief review of an emerging technique. Anal Lett 37:1013-1023.
28. Cruciani G, Carosati E, De Boeck B, Ethirajulu K, Mackie C, Howe T, Vianello R. 2005. MetaSite: Understanding metabolism in human cytochromes from the perspective of the chemist. J Med Chem 48:6970-6979.
29. 3 antagonist in rats, dogs and monkeys. Drug Metab Dispos 32:848-861.
30. Dalvie D. 2000. Recent advances in the applications of radioisotopes in drug metabolism, toxicology and pharmacokinetics. Curr Pharm Des 6:1009-1028.
31. Dalvie D, O'Donnell J. 1998. Characterization of polar urinary metabolites by ion-spray tandem mass spectrometry. Rapid Commun Mass Spectrom 12:419-422.
32. De Brabander HF, De Wasch K, Impens S, Schilt R, Leloux MS. 2001. Gas chromatography-mass spectrometry for residue analysis: Some basic concepts. Chromatogr Sci Ser 86:441-454.
33. Dear GJ, Plumb RS, Sweatman BC, Ayrton J, Lindon JC, Nicholson JK, Ismail IM. 2000. Mass directed peak selection, an efficient method of drug metabolite identification using directly coupled liquid chromatography-mass spectrometry-nuclear magnetic resonance spectroscopy. J Chromatogr B Biomed Sci Appl 748:281-293.
34. Deng Y, Wu J-T, Zhang H, Olah TV. 2004. Quantitation of drug metabolites in the absence of pure metabolite standards by high-performance liquid chromatography coupled with a chemiluminescence nitrogen detector and mass spectrometer. Rapid Commun Mass Spectrom 18:1681-1685.
35. DiMasi JA, Hansen RW, Grabowski HG. 2003. The price of innovation: New estimates of drug development costs. J Health Econ 22:151-185.
36. Dixon RW, Peterson DS. 2002. Development and testing of a detection method for liquid chromatography based on aerosol charging. Anal Chem 74:2930-2937.
37. Dolan JW. 2002. Temperature selectivity in reversed-phase high performance liquid chromatography. J Chromatogr A 965:195-205.
38. Duckett CJ, Bailey NJC, Walker H, Abou-Shakra J, Wilson ID, Lindon JC, Nicholson JK. 2002. Quantitation in gradient high performance liquid chromatography/inductively coupled mass spectrometry using diclofenac and chlorpromazine. Rapid Commun Mass Spectrom 16:245-247.
39. Dulik DM, Schaefer WH, Bordas-Nagy J, Simpson RC, Murphy DM, Rhodes GR. 1996. Applications of tandem liquid chromatography/mass spectrometry in drug biotransformation and quantification studies. In: Burlingame A, Carr SA, editors. Mass spectrometry in the biological sciences. Totowa, NJ: Humana Press, pp 425-449.
40. Dumasia M, Morelli I, Teale P. 2004. Detection of eltenac in the horse: Identification of Phase I metabolites in urine by capillary gas chromatography-mass spectrometry and the determination of excretion profile by liquid chromatography-mass spectrometry. Chromatographia 59:5115-8121.
41. Eddershaw PJ, Dickins M. 1999. Advances in in vitro drug metabolism screening. Pharm Sci Technol Today 2:13-19.
42. Egnash LA, Ramanathan R. 2002. Comparison of heterogeneous and homogeneous radioactivity flow detectors for simultaneous profiling and LC-MS/MS characterization of metabolites. J Pharm Biomed Anal 27:271-284.
43. Elmore D, Bhattacharyya MH, Sacco-Gibson N, Peterson DP. 1990. Calcium-41 as a long-term biological tracer for bone resorption. Nucl Inst Methods Phys Res B52:531-535.
44. Evans DC, Watt AP, Nicoll-Griffith DA, Baillie T. 2004. Drug-protein adducts: An industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol 17:3-6.
45. Fang J, Semple HA, Song J. 2004. Determination of metoprolol and its four metabolites in dog plasma. J Chromatogr B Anal Technol Biomed Life Sci 809:9-14.
46. Fries HE, Evans CA, Ward KW. 2005. Evaluation of evaporative light-scattering detection for metabolite quantitation without authentic analytical standards or radiolabel. J Chromatogr B Anal Technol Biomed Life Sci 819:339-344.
47. Fujinari EM, Courthaudon LO. 1992. Nitrogen-specific liquid chromatography detector based on chemiluminescence: Application to the analysis of ammonium nitrogen in waste water. J Chromatogr 592:209-214.
48. Fura A, Shu Y, Zhu M, Hanson RL, Roongta V, Humphreys WG. 2004. Discovering drugs through biological transformation: Role of pharmacologically active metabolites in drug discovery. J Med Chem 47:4339-4351.
49. Gaddamidi V, Scott MT, Swain SR, Brown AM, Young G, Hashinger BM, Lee D, Bookhart W. 2004. Sensitive on-line detection of radioisotopes using LC-ARC applications in agrochemical research. Drug Metab Rev 36:256.
50. Garner RC. 2000. Accelerator mass spectrometry in pharmaceutical research and development - A new ultrasensitive analytical method for isotope measurement. Curr Drug Metab 1:205-213.
51. 14C-labeled (R)-6-[Amino(4-chlorophenyl)(1-methyl- 1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone (R115777), a farnesyl transferase inhibitor. Drug Metab Dispos 30:823-830.
52. Godejohann M, Tseng L-H, Braumann U, Fuchser J, Spraul M. 2004. Characterization of a paracetamol metabolite using on-line LC-SPE-NMR-MS and a cryogenic NMR probe. J Chromatogr A 1058.
53. Grabowski H, Vernon J, DiMasi JA. 2002. Returns on research and development for 1990 drug introductions. Pharmacoeconomics 20: 11-29.
54. Greibrokk T, Andersen T. 2003. High-temperature liquid chromatography. J Chromatogr A 1000:743-755.
55. Griffin JL, Shockcor JP. 2004. Metabolic profiles of cancer cells. Nat Rev Cancer 4:551-561.
56. Guan X, Huffman B, Dwivedi C, Matthees DP. 2003. A Simultaneous liquid chromatography/mass spectrometric assay of glutathione, cysteine, homocysteine and their disulfides in biological samples. J Pharm Biomed Anal 31:251-261.
57. Hager JW. 2002a. A new linear ion trap mass spectrometer. Rapid Commun Mass Spectrom 16:512-526.
58. Hager J W. 2002b. A new linear trap mass spectrometer. Rapid Commun Mass Spectrom 16:512-540.
59. linear ion trap (Q TRAP™) mass spectrometer. Rapid Commun Mass Spectrom 17:1056-1064.
60. Hallensleben K, Raida M, Habermehl G. 2000. Identification of a new metabolite of macrolide immunosuppressant, like rapamycin and SDZ RAD, using high performance liquid chromatography and electrospray tandem mass spectrometry. J Am Soc Mass Spectrom 11:516-525.
61. Herman JL. 2005. The use of turbulent flow chromatography and the isocratic focusing effect to achieve on-line clean-up and concentration of neat biological samples for low-level metabolite analysis. Rapid Commun Mass Spectrom 19:696-700.
62. Hop CECA. 2004. Applications of quadrupole-time-of-flight mass spectrometry to facilitate metabolite identification. Am Pharm Rev 7:76-79.
63. Hop CECA, Prakash C. 2005. Metabolite identification by LC-MS: Applications in drug discovery and development. In: Chowdhury SK, editor. Identification and quantification of drugs, metabolites and metabolizing enzymes by LC-MS. New York: Elsevier. pp 123-158.
64. Hop CECA, Chen Y, Yu LJ. 2005. Uniformity of ionization response of structurally diverse analytes using a chip-based nanoelectrospray ionization source. Rapid Commun Mass Spectrom 19:3139-3142.
65. Hopfgartner G, Zell M. 2005. Q trap MS: A new tool for metabolite identification. In: Korfmacher W, editor. Using mass spectrometry for drug metabolism studies. Boca Raton, FL: CRC Press, pp 277-304.
66. Hopfgartner G, Chernushevich IV, Covey T, Plomley JB, Bonner R. 1999. Exact mass measurement of product ions for the structural elucidation of drug metabolites with a tandem quadrupole orthogonal-acceleration time-of-flight mass spectrometer. J Am Soc Mass Spectrom 10:1305-1314.
67. Hopfgartner G, Husser C, Zell M. 2003. Rapid screening and characterization of drug metabolites using a new quadrupole-linear ion trap mass spectrometer. J Mass Spectrom 38:138-150.
68. Hopfgartner G, Varesio E, Tschappat V, Grivet C, Bourgogne E, Leuthold LA. 2004. Triple quadrupole linear ion trap mass spectrometer for the analysis of small molecules and macromolecules. J Mass Spectrom 39:845-855.
69. Horning EC, Horning MG, Carroll DI, Dzidic I, Stillwell RN. 1973. New picogram detection system based on a mass spectrometer with an external ionization source at atmospheric pressure. Anal Chem 45:936-943.
70. Hu Q, Noll RJ, Li H, Makarov AA, Hardman M, Cooks RG. 2005. The orbitrap: A new mass spectrometer. J Mass Spectrom 40:430-443.
71. Hughes I, Hunter D. 2001. Techniques for analysis and purification in high-throughput chemistry. Curr Opin Chem Biol 5:243-247.
72. Ikonomou MG, Blades AT, Kebarle P. 1991. Electrospray-ion spray: A comparison of mechanisms and performance. Anal Chem 63:1989-1998.
73. Ilett KF, Ethell BT, Maggs JL, Davis TME, Batty KT, Burchell B, Binh TQ, Thu LTA, Hung NC, Pirmohamed M, Park BK, Edwards G. 2002. Glucuronidation of dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-glucuronyltransferases. Drug Metab Dispos 30:1005-1012.
74. Jackson PJ, Brownsill RD, Taylor AR, Walther B. 1995. Use of electrospray ionisation and neutral loss liquid chromatography/tandem mass spectrometry in drug metabolism studies. J Mass Spectrom 20:446-451.
75. Jamel M, Ouyang Z, Zhao W, Zhu M, Wu WW. 2003. A strategy for metabolite identification using triple-quadupole mass spectrometry with enhanced resolution and accurate mass capability. Rapid Commun Mass Spectrom 17:2732-2740.
76. Johnson KA, Plumb R. 2005. Investigating the human metabolism of acetaminophen using UPLC and exact mass oa-TOF MS. J Pharm Biomed Anal 39:805-810.
77. Johnson KA, Prakash C. 2005. Metabolism, excretion and pharmacokinetics of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)- acetic acid, an EP-2 receptor selective PGE2 agonist, in male and female Sprague-Dawley rats. Drug Metab Dispos 33:1191-1201.
78. Kadlubar FF, Miller JA, Miller EC. 1997. Hepatic microsomal W-glucuronidation and nucleic acid binding of N-hydroxy arylamines in relation to urinary bladder carcinogenesis. Cancer Res 37:805-814.
79. Kalgutkar AS, Gardner I, Obach RS, Shaffer CL, Callegari E, Henne KR, Mutlib AE, Dalvie DK, Lee JS, Nakai Y, O'Donnell JP, Boer J, Harriman SP. 2005. A comprehensive listing of bioactivation pathways of organic functional groups. Curr Drug Metab 6:161-225.
80. Kamel A, Munson B. 2004. Collisionally induced dissociation of purine antiviral agents: Mechanisms of ion formation using gas phase hydrogen/deuterium exchange and electrospray ionization tandem mass spectrometry. Eur J Mass Spectrom 10:239-257.
81. Kamel A, Prakash C. 2006. High performance liquid chromatography/ atmospheric pressure ionization/tandem mass spectrometry (HPLC/API/MS/MS) in drug metabolism and toxicology studies. Curr Drug Metab 7:828-843.
82. Kamel A, Davis J, Potchoiba MJ, Parkash C. 2006. Metabolism, pharmacokinetics, tissue distribution and excretion of the potent tachykinin NK1 receptor antagonist (CP-122, 721) in the rat: Characterization of a novel oxidative pathway. Xenobiotica 36:235-258.
83. Kassahun K, Mattiuz E, Nyhart J, Eldon.Obermeyer B, Gillespie T, Murphy A, Goodwin RM, Tupper D, Callaghan JT, Lemberger L. 1997. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos 25:81-93.
84. Kebarle P, Tang L. 1993. From ions in solution to ions in the gas phase: The mechanism of electrospray mass spectrometry. Anal Chem 65:972A-986A.
85. Keski-Hynnila H, Raanaa K, Forsberg M, Mannisto P, Taskinen J, Kostiainen R. 2001. Quantitation of entacapone glucuronide in rat plasma by on-line coupled restricted-access media column liquid chromatographytandem mass spectrometry. J Chromatogr B Biomed Sci Appl 759:227-236.
86. King R, Fernandez-Metzler C. 2006. The use of qtrap technology in drug metabolism. Curr Drug Metab 7:541-545.
87. Korfmacher WA, Bryant MS, Cox KA, Ng K, Veals J, Clarke N, Hsieh Y, Rindgen D, Tandler P, Wainhaus S, White RE. 2001. Strategies for optimizing the use of mass spectrometry for drug metabolism participation in new drug discovery. Adv Mass Spectrom 15:679-680.
88. Kostiainen R, Kotiaho T, Kuuranne T, Auriola S. 2003. Liquid chromatography/atmospheric pressure ionization-mass spectrometry in drug metabolism studies. J Mass Spectrom 38:357-372.
89. Kulanthaivel P, Barbuch RJ, Davidson RS, Yi P, Rener GA, Mattiuz EL, Hadden CE, Goodwiin LA, Ehlhardt WJ. 2004. Selective reduction of N-oxides to amines: Application to drug metabolism. Drug Metab Dispos 32:966-972.
90. Kuuranne T, Kotiaho T, Pedersen-Bjergaard S, Rasmussen KE, Leinonen A, Westwood S, Kostiainen R. 2003. Feasibility of a liquid-phase microextraction sample clean-up and LC-MS/MS screening method for selected anabolic steroid glucuronides in biological samples. J Mass Spectrom 38:16-26.
91. Lane S, Boughtflower B, Mutton I, Paterson C, Farrant D, Taylor N, Blaxill Z, Carmody C, Borman P. 2005. Toward single-calibrant quantification in HPLC. A comparison of three detection strategies: Evaporative light scattering, chemiluminescent nitrogen and proton NMR. Anal Chem 77:4354-4365.
92. Leavens WJ, Lane SJ, Carr RM, Waterhouse I. 2002. Derivatization for liquid chromatography/electrospray mass spectrometry: Synthesis of Tris-(trimethoxyphenyl)phosphonium compounds and their derivatives of amine and carboxylic acids. Rapid Commun Mass Spectrom 16:433-441.
93. Lee MS, Kerns EH. 1999. LC/MS applications in drug development. Mass Spectrom Rev 18:187-279.
94. Lee HW, Won KJ, Cho SH, Ha YH, Park WS, Yim HT, Baek M, Rew JH, Yoon SH, Yim SV, Chung JH, Lee KT. 2005. Quantitation of niflumic acid in human plasma by high-performance liquid chromatography with ultraviolet absorbance detection and its application to a bioequivalence study of talniflumate tablets. J Chromatogr B Anal Technol Biomed Life Sci 821:215-220.
95. Li AC, Alton D, Bryant MS, Shou WZ. 2005a. Simultaneously quantifying parent drugs and screening for metabolites in plasma pharmacokinetic samples using selected reaction monitoring information-dependent acquisition on a Q trap instrument. Rapid Commun Mass Spectrom 19:1943-1950.
96. Li Y, Li AC, Shi H, Zhou S, Shou WZ, Jiang X, Naidong W, Lauterbach JH. 2005b. The use of chemical derivatization to enhance liquid chromatography/ tandem mass spectrometric determination of 1-hydroxypyrene, a biomarker for polycyclic aromatic hydrocarbons in human urine. Rapid Commun Mass Spectrom 19:3331-3338.
97. 14C in non-volatile samples by accelerator mass spectrometry. Anal Chem 76:328-334.
98. Liu DQ, Hop CECA. 2005. Strategies for characterization of drug metabolites using liquid chromatography-tandem mass spectrometry in conjunction with chemical derivatization and on-line H/D exchange approaches. J Pharm Biomed Anal 37:1-18.
99. Liu DQ, Hop CECA, Beconi MG, Mao A, Chiu S-HL. 2001. Use of on-line hydrogen/deuterium exchange to facilitate metabolite identification. Rapid Commun Mass Spectrom 15:1832-1839.
100. Liu Y, Grinberg N, Thompson KC, Wenslow RM, Neue UD, Morrison D, Walter TH, O' Gara JE, Wyndham KD. 2005. Evaluation of a C18 hybrid stationary phase using high-temperature chromatography. Anal Chim Acta 554:144-151.
101. Loboz KK, Gross AS, Ray J, McLachlan AJ. 2005. HPLC assay for bupropion and its major metabolite in human plasma. J Chromatogr B Anal Technol Biomed Life Sci 823:115-121.
102. March RE. 1997. An introduction to quadrupole ion trap mass spectrometry. J Mass Spectrom 32:351-369.
103. Marshall AG. 1996. Ion cyclotron resonance and nuclear magnetic resonance spectroscopies: Magnetic partners for elucidation of molecular structure and reactivity. Ace Chem Res 29:307-316.
104. Martino R, Malet-Martino M, Guard V. 2000. Fluorine nuclear magnetic resonance, a privileged tool for metabolic studies of fluoropyrimidine drugs. Curr Drug Metab 1:271-303.
105. Matthews BT, Higginson PD, Lyons R, Mitchell JC, Sach NW, Snowden MJ, Taylor MR, Wright AG. 2004. Improving quantitative measurements for the evaporative light scattering detector. Chromatographia 60:625-633.
106. Mauriala T, Chauret N, Oballa R, Nicol-Griffith DA, Bateman KP. 2005. A strategy for identification of drug metabolites from dried blood spots using triple-quadrupole/linear ion trap hybrid mass spectrometry. Rapid Commun Mass Spectrom 19:1984-1992.
107. Mayol RF, Jajoo HK, Klunk J, Blair IA. 1991. Metabolism of the antipsychotic drug tiospirone in humans. Drug Metab Dispos 19:394-399.
108. McCarthy R, Ganache P, Asa D. 2005. Compound purity assessment and impurity testing with corona CAD. GIT Lab J, Eur 9:26-27.
109. Meier H, Blaschke G. 2000. Capillary electrophoresis-mass spectrometry, liquid chromatography-mass spectrometry and nanoelectrospray-mass spectrometry of praziquantel metabolites. J Chromatogr B 748:221-231.
110. Miao Z, Kamel A, Prakash C. 2005. Characterization of a novel metabolite intermediate of ziprasidone in hepatic cytosolic fractions of rat, dog and human by ESI-MS/MS, H/D exchange and chemical derivatization. Drug Metab Dispos 33.
111. Mortishire-Smith RJ, O'Connor D, Castro-Perez JM, Kirby J. 2005. Accelerated throughput metabolic route screening in early drug discovery using high-resolution liquid chromatography/quadrupole time-of-flight mass spectrometry and automated data analysis. Rapid Commun Mass Spectrom 19:2659-2670.
112. Mourey TH, Oppenheimer LE. 1984. Use of an evaporative light-scattering mass detector in sedimentation field flow fractionation. Anal Chem 56:2427-2434.
113. Mutlib AE, Shockor JP. 2003. Application of LC/MS, LC/NMR, NMR and stable isotopes in identifying and characterizing metabolites. In: Lee JS, Obach RS, Fisher MB, editors. Drug metabolizing enzymes: Cytochrome P450 and other enzymes in drug discovery and development. New York: Marcel Dekker, Inc. pp 33-86.
114. Nassar A-EF. 2003. Online hydrogen-deuterium exchange and a tandemquadrupole time-of-flight mass spectrometer coupled with liquid chromatography for metabolite identification in drug metabolism. J Chromatogr Sci 41:398-404.
115. Nassar A-EF, Bjorge SM, Lee DY. 2003. On-line liquid chromatography- accurate radioisotope counting coupled with a radioactivity detector and mass spectrometer for metabolite identificaiton in drug discovery and development. Anal Chem 75:785-790.
116. Nassar A-EF, Kamel AM, Clarimont C. 2004a. Improving decision-making process in the structural modification of drug candidates: Enhancing metabolic stability. Drug Discov Today 9:1020-1028.
117. Nassar A-EF, Kamel AM, Clarimont C. 2004b. Improving decision-making process in the structural modification of drug candidates: Reducing toxicity. Drug Discov Today 9:1055-1064.
118. Nedderman ANR, Savage ME, White KL, Walker DK. 2004. The use of 96-well scintiplates to facilitate definitive metabolism studies for drug candidates. J Pharm Biomed Anal 34:607-617.
119. Norwood DL, Qiu F. 2004. Strategies for the analysis of pharmaceutical excipients and their trace level impurities. Am Pharm Rev 7:92-99.
120. Obach RS. 2003. Drug-drug interactions: An important negative attribute in drugs. Drug Discov Today 39:301-338.
121. 14C-quantification of biochemical samples. Int J Mass Spectrom 218:255-264.
122. Ohashi N, Furuuchi S, Yoshikawa M. 1998. Usefulness of the hydrogen-deuterium exchange method in the study of drug metabolism using liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 18:325-334.
123. 19F-nuclear magnetic resonance and gas chromatography-electron capture detection in the quantitative analysis of fluorine-containing metabolites in urine of sevoflurane-anaesthetised patients. Xenobiotica 34:301-316.
124. Parkinson A. 2001. Biotransformation of xenobiotics. In: Klaassen CD, editor. Casarett and Doul's toxicology: The basic science of poisons. New York: McGraw-Hill. pp 133-224.
125. Petritis K, Elfakir C, Dreux M. 2001. HPLC-CLND for the analysis of underivatized amino acids. LC-GC Eur 14:389-395.
126. Prakash C, Cui D. 1997. Metabolism and excretion of a new antianxiety drug candidate, CP-93,393, in cynomolgus monkeys. Identification of the novel pyrimidine ring cleaved metabolites. Drug Metab Dispos 25:1395-1406.
127. Prakash C, Soliman V. 1997. Metabolism and excretion of a novel antianxiety drug candidate, CP-93,393, in long-evans rats. Differentiation of regioisomeric glucuronides by LC/MS/MS. Drug Metab Dispos 25:1288-1297.
128. 14C-labeled ziprasidone. Drug Metab Dispos 25:206-218.
129. Prakash C, Kamel A, Gummerus J, Wilner K. 1997b. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. Drug Metab Dispos 25:863-872.
130. Prakash C, Kamel A, Cui D. 1997c. Identification of novel benzisothiazole cleaved products of ziprasidone. Drug Metab Dispos 25:897-901.
131. Prakash C, Kamel A, Miao Z. 2004. Radiochemical tracers: Essential tools for the drug metabolism studies. In: Dean DC, Filer CN, McCarthy KE, editors. Synthesis and application of isotopically labelled compounds, Vol. 8. West Sussex, UK: John Wiley & Sons Ltd. pp 115-120.
132. Preuss R, Koch HM, Angerer J. 2005. Biological monitoring of the five major metabolites of di-(2-ethylhexyl)phthalate (DEHP) in human urine using column-switching liquid chromatography-tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 816:269-280.
133. Riley RJ, Martin IJ, Cooper AE. 2002. The influence of DMPK as an integrated partner in modern drug discovery. Curr Drug Metab 3:527-550.
134. Robb DB, Covey TR, Bruins AP. 2000. Atmospheric pressure photoionization: An ionization method for liquid chromatography-mass spectrometry. Anal Chem 72:3653-3659.
135. Rodrigues AD. 2002. Drug-drug interactions. In: Rodrigues AD, editor. Drugs and the pharmaceutical sciences. New York: Marcel Dekker. pp650
136. Roffey SJ, Cole S, Comby P, Gibson D, Jezequel SG, Nedderman ANR, Smith DA, Walker DK, Wood N. 2003. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos 31:731-741.
137. Rufer CE, Glatt H, Kulling SE. 2006. Structural elucidation of hydroxylated metabolites of the isoflavan equol by gas chromatography-mass spectrometry and high-performance liquid chromatography-mass spectrometry. Drug Metab Dispos 34:51-60.
138. Sanagi MM, See HH. 2005. High temperature liquid chromatography on a poly(styrene-divinylbenzene) stationary phase. J Liquid Chromatogr Relat Technol 28:3065-3076.
139. 19F-NMR spectroscopy and directly coupled HPLC-NMR-MS. Xenobiotica 29:77-91.
140. Schaefer WH, Dixon JFrank. 1996. Effect of high-performance liquid chromatography mobile phase components on sensitivity in negative atmospheric pressure chemical ionization liquid chromatography-mass spectrometry. J Am Soc Mass Spectrom 7:1059-1069.
141. Schmidt A, Karas M, Dülcks T. 2003. Effect of different solution flow rates on analyte sgnals in nano-ESI MS, or: When does ESI turn into nano-ESI? J Am Soc Mass Spectrom 14:492-500.
142. Shaffer CL, Gunduz M, O'Connell TN, Obach RS, Yee S. 2005. Biotransformation of a GABAA receptor partial agonist in sprague-dawley rats and cynomolgus monkeys: Identification of two unique W-carbamoyl metabolites. Drug Metab Dispos 33:1688-1699.
143. Shevchenko A, Chernushevich I, Ens W, Standing KG, Thomson B, Wilm M, Mann M. 1997. Rapid 'de novo' peptide sequencing by a combination of nanoelectrospray, isotopic labeling and a quadrupole/time-of-flight mass spectrometer. Rapid Commun Mass Spectrom 11:1015-1024.
144. Shockcor JP, Unger SE, Wilson ID, Foxall PJD, Nicholson JK, Lindon JC. 1996. Combined HPLC, NMR spectroscopy, and ion-trap mass spectrometry with application to the detection and characterization of xenobiotic and endogenous metabolites in human urine. Anal Chem 68:4431-4435.
145. Shpkova M, Armstrong VW, Wielaqnd E, Niedmann PD, Schutz E, BrennerWeib G, Voihsel M, Braun F, Oellerich M. 1999. Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br J Pharmacol 126:1075-1082.
146. Sidelmann UG, Bjornsdottir I, Shockcor JP, Hansen SH, Lindon JC, Nicholson JK. 2001. Directly coupled HPLC-NMR and HPLC-MS approaches for the rapid characterization of drug metabolites in urine: Application to the human metabolism of naproxen. J Pharm Biomed Anal 24:569-579.
147. Sin CH, Lee ED, Lee ML. 1991. Atmospheric pressure ionization time-of-flight mass spectrometry with a supersonic beam. Anal Chem 63:2897-2900.
148. Sinz MW, Podoll T. 2002. The mass spectrometer in drug metabolism. In: Rossi DT, Sinz MW, editors. Mass spectrometry in drug discovery. New York: Marcel Dekker. pp 271-336.
149. Smith DA, Obach RS. 2005. Seeing through the MIST: Abundance versus percentage. Commentary on metabolites in safety testing. Drug Metab Dispos 33:1409-1417.
150. Smith D, Schmid E, Jones B. 2002. Do drug metabolism and pharmacokinetic departments make any contribution to drug discovery. Clin Pharmacokinet 41:1005-1019.
151. Soglia JR, Harriman SP, Zhao S, Barberia J, Cole MJ, Boyd JG, Contillo LG. 2004. The development of a higher throughput reactive intermediate assay incorporating micro-bore liquid chromatography-micro-electrospray ionisation-tandem mass spectrometry and glutathione ethyl ester as an in vitro conjugating agent. J Pharm Biomed Anal 36:105-116.
152. Spraul M, Hofmann M, Dvortsak P, Nicholson JK, Wilson ID. 1993. High-performance liquid chromatography coupled to high-field proton nuclear magnetic resonance spectroscopy: Application to the urinary metabolites of ibuprofen. Anal Chem 65:327-330.
153. Spraul M, Freund AS, Nast RE, Withers RS, Maas WE, Corcoran O. 2003. Advancing NMR sensitivity for LC-NMR-MS using a cryoflow probe: Application to the analysis of acetaminophen metabolites in urine. Anal Chem 75:1536-1541.
154. Staack RF, Varesio E, Hopfgartner G. 2005. The combination of liquid chromatography/tandem mass spectrometry and chip-based infusion for improved screening and characterization of drug metabolites. Rapid Commun Mass Spectrom 19:618-626.
155. Sutton KL, Caruso JA. 1999. Liquid chromatography-inductively coupled plasma mass spectrometry. J Chromatogr A 856:243-258.
156. n and the chemiluminescent nitrogen detector. Anal Chem 74:3232-3238.
157. Thevis M, Makarov AA, Horning S, Schanzer W. 2005. Mass spectrometry of stanozolol and its analogues using electrospray ionization and collision-induced dissociation with quadrupole-linear ion trap and linear ion trap-orbitrap hybrid mass analyzers. Rapid Commun Mass Spectrom 19:3369-3378.
158. Van de Goor TA. 2004. Moving liquid chromatography from nano to chip. Pharm Genomics 4:20-22.
159. Vogel JS. 1992. Rapid production of graphite without contamination for biomedical AMS. Radiocarbon 34:344-350.
160. Wang N, Szoatek B, Buck RC, Folsom PW, Sulecki LM, Capka V, Berti WR, Gannon JT. 2005a. Fluorotelomer alcohol biodegradation - Direct evidence that perfluorinated carbon chains breakdown. Environ Sci Technol 39:7516-7528.
161. Wang Y, Zhang W, Dong Y, Fan R, Sheng G, Fu J. 2005b. Quantification of several monohydroxylated metabolites of polycyclic aromatic hydrocarbons in urine by high-performance liquid chromatography with fluorescence detection. Anal Bioanal Chem 383:804-809.
162. Watt AP, Mortishire-Smith RJ, Grhard U, Thomas T. 2003. Metabolite identification in drug discovery. Drug Discov Dev 6:57-65.
163. Weigl BH, Bardell RL, Cabrera CR. 2003. Lab-on-a-chip for drug development. Adv Drug Deliv Rev 55:349-377.
164. White RE. 2000. High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery. Annu Rev Pharm Toxicol 40:133-157.
165. Wilson ID, Plumb R, Granger J, Major H, Williams R, Lenz EM. 2005. HPLC-MS-based methods for the study of metabonomics. J Chromatogr B 817:67-76.
166. Wrona M, Mauriala T, Bateman KP, Mortishire-Smith RJ, O'Connor D. 2005. 'All-in-one' analysis for metabolite identification using liquid chromatography/hybrid quadrupole time-of-flight mass spectrometry with collision energy switching. Rapid Commun Mass Spectrom 19:2597-2602.
167. Xia Y-Q, Miller JD, Bakhtiar R, Franklin RB, Liu DQ. 2003. Use of a quadrupole linear ion trap mass spectrometer in metabolite identification and bioanalysis. Rapid Commun Mass Spectrom 17:1137-1145.
168. Xie J, Miao Y, Shih J, Tai Y-C, Lee TD. 2005. Microfluidic platform for liquid chromatography-tandem mass spectrometry analysis of complex peptide mixture. Anal Chem 77:6947-6953.
169. Xu X, Ziegler RG, Waterhouse DJ, Saavedra JE, Keefer LK. 2002. Stable isotope dilution high-performance liquid chromatography-electrospray ionization mass spectrometry method for endogenous 2- and 4-hydroxyestrones in human urine. J Chromatogr B Anal Technol Biomed Life Sci 780:315-330.
170. Yamashita M, Fenn JB. 1984a. Electrospray ion source. Another variation on the free-jet theme. J Phys Chem 88:4451-4459.
171. Yamashita M, Fenn JB. 1984b. Negative ion production with the electrospray ion source. J Phys Chem 88:4671-4675.
172. Yin H, Greenberg GE, Fischer V. 2000. Application of wallac microbeta radioactivity counter and wallac scintiplate in metabolite profiling and identification studies. Application Note, Perkin-Elmer Life Sci
173. Yin H, Killeen K, Brennen R, Sobek D, Werlich M, Van de Goor TA. 2005. Microfluidic chip for peptide analysis with an integrated HPLC column, sample enrichment column and nanoelectrospray tip. Anal Chem 77:527-533.
174. Ynddal L, Hansen SH. 2003. On-line turbulent-flow chromatography-high- performance liquid chromatography-mass spectrometry for fast sample preparation and quantitation. J Chromatogr A 1020:59-67.
175. Young G, Ellis W, Ayrton J, Hussey E, Adamkiewicz B. 2001. Accelerator mass spectrometry (AMS): Recent experience of its use in a clinical study and the potential future of the technique. Xenobiotica 31:619-632.
176. Yu LJ, Chen Y, DeNinno MP, O'Connell TN, Hop CECA. 2005. Identification of a novel glutathione adduct of diclofenac, 4′-hydroxy-2′- glutathiondeschloro-diclofenac, upon incubation with human liver microsomes. Drug Metab Dispos 33:484-488.
177. Zhang N, Fountain ST, Bi H, Rossi DT. 2000. Quantification and rapid metabolite identification in drug discovery using API time-of-flight LC/MS. Anal Chem 72:800-806.
178. Zhang H, Zhang D, Ray K. 2003. A software filter to remove interference ions from drug metabolites in accurate mass liquid chromatography/mass spectrometric analyses. J Mass Spectrom 38:1110-1112.
179. Zhao W, Wang L, Zhang D, Zhu M. 2004. Rapid and sensitive determination of enzyme kinetics of drug metabolism using HPLC coupled with a stop-flow radioactivity flow detector. Drug Metab Rev 36:257.